

| | | | | |
|--|--|--|--|-------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 06275-0460US1 | Application No. 10/542,044 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Andrew David Morley et al. | | |
| | | Filing Date July 13, 2005 | Group Art Unit 1626 | |

| U.S. Patent Documents | | | | | | | |
|-----------------------|-----------|-----------------|------------------|--------------------------------|-------|----------|----------------------------|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
| | AA | 5,258,357 | 11/02/1993 | Muenster et al. | | | |
| | AB | 5,571,810 | 11/05/1996 | Matsuo et al. | | | |
| | AC | 5,679,670 | 10/21/1997 | Dean et al. | | | |
| | AD | 6,048,880 | 04/11/2000 | Kawai et al. | | | |
| | AE | 6,380,214 | 04/30/2002 | Gant et al. | | | |
| | AF | 6,699,854 | 03/02/2004 | Wang et al. | | | |
| | AG | 6,809,088 | 10/26/2004 | Chabrier de Lassauniere et al. | | | |
| | AH | 7,125,896 | 10/24/2006 | Faull et al. | | | |
| | AI | 7,166,639 | 01/23/2007 | Wan et al. | | | |
| | AJ | 7,358,376 | 04/15/2008 | Baxter et al. | | | |
| | AK | US-2006-0111431 | 05/25/2006 | Morley et al. | | | |
| | AL | US-2006-0058522 | 03/16/2006 | Faull et al. | | | |
| | AM | US-2007-0015819 | 01/18/2007 | Faull et al. | | | |

| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | |
|---|-----------|-----------------|------------------|--------------------------|-------|----------|---------------------------|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation |
| | | | | | | | Yes No |
| | AN | EP 0202538 | 11/26/1986 | EP | | | English Abstract attached |
| | AO | EP 0853083 | 07/15/1998 | EP | | | |
| | AP | EP 0908456 | 04/14/1999 | EP | | | English Abstract attached |
| | AQ | GB 1468012 | 03/23/1977 | United Kingdom | | | |
| | AR | GB 2195634 | 04/13/1988 | United Kingdom | | | |
| | AS | WO 98/02430 | 01/22/1998 | WIPO | | | |
| | AT | WO 98/54116 | 12/03/1998 | WIPO | | | |
| | AU | WO 99/46244 | 09/16/1999 | WIPO | | | |
| | AV | WO 00/71532 | 11/30/2000 | WIPO | | | |
| | AW | WO 01/58890 | 08/16/2001 | WIPO | | | |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 06275-0460US1 | Application No. 10/542,044 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Andrew David Morley et al. | |
| | | Filing Date July 13, 2005 | Group Art Unit 1626 |

Foreign Patent Documents or Published Foreign Patent Applications

| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
|------------------|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|----|
| | | | | | | | Yes | No |
| | AX | WO 01/98290 | 12/27/2001 | WIPO | | | | |
| | AY | WO 02/30353 | 04/18/2002 | WIPO | | | | |
| | AZ | WO 03/010158 | 02/06/2003 | WIPO | | | | |
| | AAA | WO 03/010163 | 02/06/2003 | WIPO | | | | |
| | ABB | WO 03/029241 | 04/10/2003 | WIPO | | | | |
| | ACC | WO 03/028731 | 04/10/2003 | WIPO | | | | |
| | ADD | WO 2004/063185 | 07/29/2004 | WIPO | | | | |
| | AEE | WO 2004/063186 | 07/29/2004 | WIPO | | | | |

Other Documents (include Author, Title, Date, and Place of Publication)

| Examiner Initial | Desig. ID | Document |
|------------------|-----------|---|
| | AFF | Awada et al., "The pipeline of new anticancer agents for breast cancer treatment in 2003", <i>Critical Reviews in Oncology/Hematology</i> 48:45-63 (2003) |
| | AGG | Berkow et al., The Merck Manual of Diagnosis and Therapy, 16 th Edition, © 1992, Merck Research Laboratories, Rahway, NJ, pages 1488 and 2664 |
| | AHH | Chen et al., "TNF-R1 Signaling: A Beautiful Pathway", <i>Science</i> 296:1634-1635 (2002) |
| | AII | Compston et al., "Multiple sclerosis", <i>The Lancet</i> 359:1221-1231 (2002) |
| | AJJ | Du et al., "Aryl ureas represent a new class of anti-trypanosomal agents", <i>Chemistry & Biology</i> 7:733-742 (2000) |
| | AKK | Hartung et al., "What do we know about the mechanism of action of disease-modifying treatments in MS?" <i>J Neurol</i> 251(Suppl. 5):V/12-V/29 (2004) |
| | ALL | Karin et al., "NF-κB in cancer: from innocent bystander to major culprit", <i>Nat. Rev. Cancer</i> 2:301-310 (2002) |
| | AMM | Luo et al., "IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy", <i>J. Clin. Invest.</i> 115(10):2625-2632 (2005) |
| | ANN | Orlowski, et al., "NF-κB as a therapeutic target in cancer", <i>TRENDS in Molecular Medicine</i> 8(8):385-389 (2002) |
| | AOO | Zayed et al., "Studies on 5-aminopyrazole derivatives. Synthesis of some new fused pyrazole derivatives", <i>Monatsh. Chem.</i> 115:431-436 (1984) |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |